Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus SOX for pMMR Gastric Cancer
NCT05872685Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA). Started Dec 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05872685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872685.